Sunday, December 30, 2018 10:06:34 PM
''Anavex 2-73 reportedly binds the sigma-1 receptor in the high nanomolar and the muscarinic receptor in the low micromolar range.'' SEE # 1 BELOW.
"Preclinical Data of ANAVEX 1-41 and ANAVEX 2-73, Show Highly Potent Anti-Amnesic and Neuroprotective Activity Against Amyloid Beta (25-35) Peptide Toxicity in Alzheimer's Disease (AD) Animal Mode." # 2 BELOW.
"ANAVEX2-73 is metabolized into the pharmacologically active metabolite, ANAVEX 19-144. The apparent elimination half-life of the metabolite (21.45hr) is approximately twice that of ANAVEX2-73 (10.71 hr) hence the active metabolite result in extended activation of the sigma-1 receptor." #3 BELOW.
An extended half-life implies an increased impact on patients.
"Preclinical data reveals that ANAVEX 2-73 and ANAVEX 19-144 exhibit significant anti-amnesic, neuroprotective and anticonvulsant properties in a variety of in vitro systems and specialized animal models. These activities involve sigma-1, muscarinic and NMDA receptors as well as ion channels, indicating a unique mode of action. In AD animal models, ANAVEX 2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. ANAVEX 2-73 has shown a potential dual mechanism which may impact both amyloid and tau pathology. ANAVEX 19-144 controls seizures and the epileptogenesis process in animal models. Moreover, its neuroprotective properties may prevent the process that causes long-term damage to tissue and cells as well as biochemical and physiological alterations to the brain from epileptic seizures." (10 K Part 1, ITEM 1. BUSINESS). #4
Orevko post (# 5 below) discussed patent rights on this board in the past and says this about AVXL 2-73 and 19-144: "I read through that new application last week and it's quite interesting. It gives some additional insight into the inner workings of Anavex 2-73 and Anavex PLUS. The metabolite (Anavex 19-144) really seems to be the secret sauce. ". Many excellent posts from the past by Orevko may be located on this board, and the patent Orveko refers to is something I or we all may review to learn more about the inner workings of Anavex’s drugs.
1. Chemical Name: Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride
Therapy Type: Small Molecule (timeline)
Target Type: Other (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 2)
Company: Anavex Life Science Corp.
BACKGROUND
This compound is an agonist of the intracellular sigma-1 chaperone protein. Specifically, it is a mixed ligand for sigma1/muscarinic receptors. Expressed in most tissues and located at focal contacts between mitochondria and the endoplasmic reticulum, the sigma-1 receptor forms heterodimers with many other membrane receptors, and as such influences multiple cellular pathways and physiological processes. Anavex 2-73 reportedly binds the sigma-1 receptor in the high nanomolar and the muscarinic receptor in the low micromolar range.
The compound has been reported to have memory-preserving and neuroprotective effects in mice treated with the muscarinic receptor antagonist scopolamine, with synthetic Aß oligomer injection, or with the NMDA receptor agonist dizocilpine (Villard et al., 2011). A recent study suggested that Anavex 2-73 may block tau hyperphosphorylation (see Jan 2013 conference news and Lahmy et al., 2013).
https://www.alzforum.org/therapeutics/anavex-2-73
2. Preclinical Data of ANAVEX 1-41 and ANAVEX 2-73, Show Highly Potent Anti-Amnesic and Neuroprotective Activity Against Amyloid Beta (25-35) Peptide Toxicity in Alzheimer's Disease (AD) Animal Mode
http://www.marketwired.com/press-release/preclinical-data-anavex-1-41-anavex-2-73-show-highly-potent-anti-amnesic-neuroprotective-otc-bulletin-board-avxl-654103.htm
3. ANAVEX2-73 is metabolized into the pharmacologically active metabolite, ANAVEX 19-144.
The apparent elimination half-life of the metabolite (21.45hr) is approximately twice that of ANAVEX2-73 (10.71 hr) hence the active metabolite result in extended activation of the sigma-1 receptor.
https://anavex.com/wp-content/uploads/ANAVEX2-73-PKPD-Phase-2a-2017.pdf
4. "Preclinical data reveals that ANAVEX 2-73 and ANAVEX 19-144 exhibit significant anti-amnesic, neuroprotective and anticonvulsant properties in a variety of in vitro systems and specialized animal models. These activities involve sigma-1, muscarinic and NMDA receptors as well as ion channels, indicating a unique mode of action. In AD animal models, ANAVEX 2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. ANAVEX 2-73 has shown a potential dual mechanism which may impact both amyloid and tau pathology. ANAVEX 19-144 controls seizures and the epileptogenesis process in animal models. Moreover, its neuroprotective properties may prevent the process that causes long-term damage to tissue and cells as well as biochemical and physiological alterations to the brain from epileptic seizures." (10 K Part 1, ITEM 1. BUSINESS)
https://www.sec.gov/Archives/edgar/data/1314052/000106299311005004/form10k.htm
5. Orveko I-Hub post -Wednesday, 01/27/16 01:06:47 AM
Re: seventhwave post# 51618 0
Post # of 176791
Anavex 19-144 is the active metabolite of Anavex 2-73, i.e., when you ingest A2-73, your body metabolizes it into A19-144. A2-73 is therefore itself a drug and also a pro-drug for A19-144. One-two punch.
Dr. Vamvakides signed over Greek patent rights for A2-73 (AE 37), A19-144 (AE 37 MET), and other compounds per the following contract (effective January 29, 2007) - scroll down to the very end (Schedule A):
https://www.sec.gov/Archives/edgar/data/1314052/000108503707000289/super8k-exh10_1.htm
Most of the U.S. patent applications related to the original Greek patents are still pending, but all are either directly assigned to Anavex or are otherwise contractually owned by Anavex. I specifically asked IR about this new application and they say it is "contractually the property of Anavex."
Even though this new application (14/865862) was just published, it's priority date is March 28, 2013, same as 13/940352 and 14/395581. This is because they are all essentially "continuations" of the original Greek patent application GR2013000018 (WO2014155138). This Greek application (which is where Anavex PLUS comes from) was not part of the original contract with Vamvakides, but is still the contractual property of Anavex per the 2012 addendum to the original contract (effective January 11, 2013):
Quote:
1.1 (e) Inventions made during the term of the CONTRACT filed on or after January 29, 2007 and not falling under 1.1 (a) - (d) wherein Dr. Vamvakides is an inventor.
http://www.sec.gov/Archives/edgar/data/1314052/000106299313006497/exhibit10-81.htm
Anyway, I read through that new application last week and it's quite interesting. It gives some additional insight into the inner workings of Anavex 2-73 and Anavex PLUS. The metabolite (Anavex 19-144) really seems to be the secret sauce.
https://investorshub.advfn.com/boards/profilea.aspx?user=525667
Recent AVXL News
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM